An advisory panel to the FDA voted to recommend the agency approve the sale of a knockoff version of J&J’s arthritis drug Remicade, which had U.S. sales of $4.45 billion last year. The copy was developed by Celltrion and licensed to Pfizer.
WSJ.com: What's News US, Wall Street Journal
Tue, 02/09/2016 - 3:46pm
An advisory panel to the FDA voted to recommend the agency approve the sale of a knockoff version of J&J’s arthritis drug Remicade, which had U.S. sales of $4.45 billion last year. The copy was developed by Celltrion and licensed to Pfizer.